Has Ann Childress received payments from drug or device companies?

Yes. Drug and device makers reported $1,378,569 in general payments to Ann Childress across 981 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Ann Childress did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Ann Childress come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Ann Childress

Child & Adolescent Psychiatry · Las Vegas, NVNPI 1457303828

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (45.4%), grants and consulting fees — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Tris Pharma Inc at 38.4% of the total. 2025 is the largest year on record at $635,208, 3.8 times the $166,239 reported in 2019. Among child & adolescent psychiatry clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,378,569in general payments, 2019–2025

Across 981 payments — averaging $1405.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Tris Pharma Inc$529K
Supernus Pharmaceuticals, Inc.$417K
Ironshore Pharmaceuticals Inc.$148K
Corium, LLC$94K
Otsuka Pharmaceutical Development & Commercialization, Inc.$73K
Collegium Pharmaceutical, Inc.$44K
plus $74K from 16 others

$2,329,593in research payments, 2019–2025

Across 505 payments — averaging $4613.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Adlon Therapeutics L.p.$559K
Purdue Pharma L.p.$314K
Tris Pharma Inc$283K
Supernus Pharmaceuticals, Inc.$264K
Otsuka Pharmaceutical Development & Commercialization, Inc.$244K
Corium, LLC$182K
plus $484K from 13 others

What the payments were for

Consulting fees$164,29012%
Speaking & faculty fees$625,87945%
Grants$482,40035%
Travel & lodging$79,1966%
Food & beverage$19,6681%
Education$7,1351%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Tris Pharma Inc	68	$528,919
Supernus Pharmaceuticals, Inc.	442	$416,763
Ironshore Pharmaceuticals Inc.	209	$147,795
Corium, LLC	79	$93,822
Otsuka Pharmaceutical Development & Commercialization, Inc.	66	$72,552
Collegium Pharmaceutical, Inc.	39	$44,316
Adlon Therapeutics L.p.	10	$17,784
Vertical Pharmaceuticals, LLC	3	$15,571
Takeda Pharmaceuticals U.S.A., Inc.	21	$14,852
Noven Pharmaceuticals, Inc.	6	$9,753
Neos Therapeutics, LP	20	$8,880
Arbor Pharmaceuticals, Inc.	1	$2,520
Otsuka America Pharmaceutical, Inc.	1	$1,800
Noven Therapeutics, LLC	2	$1,100
Sunovion Pharmaceuticals Inc.	1	$820
Rhodes Pharmaceuticals L.p.	2	$680
Neurocrine Biosciences, Inc.	2	$235
Shire North American Group Inc	4	$125
Alkermes, Inc.	1	$123
MDD US Operations, LLC	1	$107
AbbVie	2	$45
Acadia Pharmaceuticals Inc	1	$6

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Onyda XR$482,400
QELBREE$324,003
Jornay PM 20mg capsules (Bottle of 100)$109,599
Azstarys$93,387
JORNAY PM$79,037
Dyanavel XR$39,254
Quillichew ER$18,087
Quillivant$17,437
ADHANSIA XR$17,165
RELEXXII$15,571
VYVANSE$14,552
Cotempla XR-ODT$7,977
Adzenys XR-ODT$6,677
Xelstrym$6,605
Evekeo$2,520
Quillivant XR$650
ARISTADA$494
INGREZZA$235
ARISTADA INITIO$123
MYOBLOC$107

How this compares

$1,378,569 in reported general payments places this provider in the 95th percentile of 26 child & adolescent psychiatry providers in Nevada.

See all child & adolescent psychiatry providers in Nevada →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Zolpidem Tartrate	12	$40

Paid to pharmacies, not to this prescriber.

Other child & adolescent psychiatry in Las Vegas

Joan CarapucciLas Vegas$7K
Emmanuel NwapaLas Vegas$7K
Rosa BellotaLas Vegas$1K
Michelle Fontenelle-GilmerLas Vegas$904
Corydon ClarkLas Vegas$777
Nina ParikhLas Vegas$516
Fernando MendezLas Vegas$249
Colin FreedmanLas Vegas$198
Olayinka HardingLas Vegas$16
Jerome NwokikeNorth Las Vegas$5K

See the full list for Nevada →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →